Use of cigarettes and smokeless tobacco (SLT) in the U.S. costs over 400,000 lives and $100 billion annually. These tobacco-related deaths and health care costs are due to tobacco-delivered toxicants, especially carcinogens. Tobacco cessation is the most effective way of reducing toxicant exposure, though relapse rates are high. High relapse rates and continued tobacco use have provoked interest in harm reduction for people who continue to use tobacco. Harm reduction for tobacco users can involve lowering the total adverse health consequences of continued tobacco use by reducing toxicant exposure. The tobacco industry appears to embrace this type of harm reduction, and markets several potential reduced exposure products (PREPs) for smokers and SLT users. The National Cancer Institute and Institute of Medicine argue for objective testing of these PREPs. No accepted testing method exists, though we have had success using a short-term clinical model for evaluating cigarette-like PREPs for smokers. This short-term model could be improved and must be adapted to evaluate oral PREPs for SLT users and smokers. A longer-term model is necessary to measure PREP-induced reductions in carcinogen exposure.
The specific aims of this proposal are to: (1) Improve the short-term clinical model for evaluating cigarette-like PREPs by allowing ad libitum puffing so that PREP-induced changes in smoking behavior can be measured, and introducing pre- and post-exposure blood sampling so that PREP nicotine delivery can be assessed. (2) Adapt the short-term clinical model so that it can be used to evaluate oral products intended for SLT users and/or smokers, and (3) Develop a longer-term clinical model for evaluating PREP carcinogen delivery. This project's overarching goal is to establish a clinical model that can be used to evaluate the marketing claims and harm reduction potential of PREPs for tobacco users. The project is consistent with NCI's Plans and Priorities for Cancer Research in 2004: """"""""Smokers may feel a false sense of security that they can significantly reduce their risk of disease by using these new products [PREPs], when no data exists to suggest that they are in fact less harmful. Scientists must examine the toxicity of these products as well as evaluate whether or not 'harm reduction' is a viable public health strategy."""""""" This proposal's clinical model will likely be an important component of a comprehensive approach to predict if PREPs for tobacco users increase, decrease, or fail to change tobacco's health risks.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA103827-03
Application #
7013624
Study Section
Biobehavioral and Behavioral Processes 3 (BBBP)
Program Officer
Djordjevic, Mirjana V
Project Start
2004-02-15
Project End
2009-01-31
Budget Start
2006-02-01
Budget End
2007-01-31
Support Year
3
Fiscal Year
2006
Total Cost
$443,928
Indirect Cost
Name
Virginia Commonwealth University
Department
Psychology
Type
Schools of Arts and Sciences
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Blank, Melissa D; Breland, Alison B; Enlow, Paul T et al. (2016) Measurement of smoking behavior: Comparison of self-reports, returned cigarette butts, and toxicant levels. Exp Clin Psychopharmacol 24:348-355
Vansickel, Andrea R; Shihadeh, Alan; Eissenberg, Thomas (2012) Waterpipe tobacco products: nicotine labelling versus nicotine delivery. Tob Control 21:377-9
Etter, Jean-Francois; Bullen, Chris; Flouris, Andreas D et al. (2011) Electronic nicotine delivery systems: a research agenda. Tob Control 20:243-8
Eissenberg, Thomas (2010) Electronic nicotine delivery devices: ineffective nicotine delivery and craving suppression after acute administration. Tob Control 19:87-8
Cobb, C O; Weaver, M F; Eissenberg, T (2010) Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. Tob Control 19:367-73
Cobb, Caroline; Ward, Kenneth D; Maziak, Wasim et al. (2010) Waterpipe tobacco smoking: an emerging health crisis in the United States. Am J Health Behav 34:275-85
Vansickel, Andrea R; Cobb, Caroline O; Weaver, Michael F et al. (2010) A clinical laboratory model for evaluating the acute effects of electronic ""cigarettes"": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev 19:1945-53
Blank, Melissa D; Eissenberg, Thomas (2010) Evaluating oral noncombustible potential-reduced exposure products for smokers. Nicotine Tob Res 12:336-43
Cohen, J E; Zeller, M; Eissenberg, T et al. (2009) Criteria for evaluating tobacco control research funding programs and their application to models that include financial support from the tobacco industry. Tob Control 18:228-34
Primack, Brian A; Walsh, Michele; Bryce, Cindy et al. (2009) Water-pipe tobacco smoking among middle and high school students in Arizona. Pediatrics 123:e282-8

Showing the most recent 10 out of 21 publications